Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29967632 | 0.79 | ALDH1A1 (0.32) | ALDH1A1HPGDALOX15ALOX12CASP1 | |
| SCHEMBL14770816 | 0.79 | TP53 (0.35) | TAAR1SLC6A2ALDH1A1ATMESR1 | |
| SCHEMBL8056864 | 0.78 | MAPT (0.33) | TAAR1SLC6A2RIPK1 | |
| SCHEMBL8701181 | 0.77 | CYP2C19 (0.38) | TAAR1SLC6A2ALDH1A1HPGDALOX15 | |
| SCHEMBL2591855 | 0.77 | TAAR1 (0.32) | TAAR1SLC6A2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL40797 | 0.77 | TAAR1 (0.32) | TAAR1SLC6A2ATMESR1ESR2 | |
| SCHEMBL28491406 | 0.76 | MAPK1 (0.33) | TAAR1SLC6A2ALDH1A1ALOX15ATM | |
| SCHEMBL28549833 | 0.76 | TAAR1 (0.31) | TAAR1SLC6A2ATMESR1ESR2 | |
| SCHEMBL11899211 | 0.74 | TAAR1 (0.30) | TAAR1SLC6A2 | |
| SCHEMBL506540 | 0.74 | NR1H2 (0.33) | ALDH1A1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067598-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | University of Florida Research Foundation, Incorporation (US) | 2024-02-29 | — | — | US | disclosed |
| US-20230364079-A1 | COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230257383-A1 | COMPOUND SERVING AS BTK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20180161324-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2018-06-14 | — | — | US | disclosed |
| US-20180065920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2018-03-08 | — | — | US | disclosed |
| US-20170368002-A1 | INKT CELL MODULATORS AND METHODS OF USING THE SAME | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2017-12-28 | — | — | US | disclosed |
| US-20170342079-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170231992-A1 | COMPOUNDS FOR USE IN TREATING ACUTE CORONARY SYNDROME AND RELATED CONDITIONS | VITAE PHARMACEUTICALS, INC. | 2017-08-17 | — | — | US | disclosed |
| US-9604908-B2 | Diether based biodegradable cationic lipids for siRNA delivery | SIMA THERAPEUTICS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9446132-B2 | Diether based biodegradable cationic lipids for siRNA delivery | SIMA THERAPEUTICS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9061063-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150057373-A1 | DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY | SIRNA THERAPEUTICS, INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8163919-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120029213-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20110200582-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| US-20100179309-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS (US) | 2010-07-15 | — | — | US | disclosed |
| US-20090306127-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368002-A1 | INKT CELL MODULATORS AND METHODS OF USING THE SAME | PBK, NFATC1, UGCG | TAAR1 3737/4885SLC6A2 4866/4885ALDH1A1 1769/4885 |
| US-20170231992-A1 | COMPOUNDS FOR USE IN TREATING ACUTE CORONARY SYNDROME AND RELATED CONDITIONS | TNNI3, FABP3, TNNT2 | TAAR1 3466/4885SLC6A2 913/4885ALDH1A1 566/4885 |
| US-20150057373-A1 | DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY | NR1H4, LDLR, LIPA | TAAR1 2256/4885SLC6A2 2711/4885ALDH1A1 2864/4885 |
| US-20110200582-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | SGMS1, SGMS2, LIPC | TAAR1 3193/4885SLC6A2 2358/4885ALDH1A1 3626/4885 |
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | FUS, SNRPE, RRBP1 | TAAR1 4462/4885SLC6A2 3602/4885ALDH1A1 4793/4885 |
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, PRMT1 | TAAR1 1012/4885SLC6A2 995/4885ALDH1A1 383/4885 |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | TAAR1 3950/4885SLC6A2 1960/4885ALDH1A1 3151/4885 |
| US-20090306127-A1 | Certain Chemical Entities, Compositions and Methods | KIF5B, KIF2C, PLK1 | TAAR1 4656/4885SLC6A2 3806/4885ALDH1A1 1977/4885 |
| US-20100179309-A1 | MODIFIED iRNA AGENTS | HNRNPA0, HNRNPA1, SNRPA | TAAR1 4533/4885SLC6A2 4291/4885ALDH1A1 2218/4885 |
| US-20180065920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, CETP, APOB | TAAR1 3607/4885SLC6A2 1922/4885ALDH1A1 2749/4885 |
| US-20240067598-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | TAAR1 4335/4885SLC6A2 3870/4885ALDH1A1 4876/4885 |
| US-20170342079-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | TAAR1 4737/4885SLC6A2 3142/4885ALDH1A1 3727/4885 |
| US-20120029213-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | DHPS, BMP2, CDK11B | TAAR1 4484/4885SLC6A2 4616/4885ALDH1A1 2475/4885 |
| US-20180161324-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPP1R1B, PPM1A, PPM1D | TAAR1 582/4885SLC6A2 1631/4885ALDH1A1 1497/4885 |
| US-20230257383-A1 | COMPOUND SERVING AS BTK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | BTK, WEE1, WEE2 | TAAR1 2971/4885SLC6A2 2629/4885ALDH1A1 4238/4885 |
| US-20230364079-A1 | COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | BTK, WEE2, WEE1 | TAAR1 2105/4885SLC6A2 948/4885ALDH1A1 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.